3-years outcome of follow-up of patients with chronic obstructive pulmonary disease successfully treated by percutaneous coronary intervention due to acute coronary syndrome

Aim To evaluate results of three-year follow-up in patients after acute coronary syndrome (ACS) associated with chronic obstructive pulmonary disease (COPD) and to identify predictors for delayed serious cardiovascular adverse (SCVAE) events.
Material and methods This prospective cohort study included 119 patients with verified COPD who had ACS after a successful urgent percutaneous coronary intervention and were discharged from the hospital without in-hospital complications. Incidence of and time to SCVAE (cardiovascular death, myocardial infarction, stroke, repeated unscheduled myocardial revascularization) were recorded. SCVAE predictors were identified with the Cox regression by stepwise inclusion of variables into the model.
Results SCVAE occurred in 33.6 % of ACS patients with COPD. The high rate of repeated myocardial revascularization mostly contributed to the development of delayed SCVAEs (19.3 % of patients). Independent predictors of SCVAE included the total number of stenoses in major coronary artery branches; ankle-brachial index; glomerular filtration rate calculated with the CKD-EPI equation; frequent COPD exacerbations; functional residual capacity of the lungs; and 6-min walk distance.
Conclusion New independent predictors of SCVAE were identified in COPD patients after ACS with percutaneous coronary intervention and stenting, including distance in the 6-min walk test, frequent COPD exacerbations, and functional residual volume of the lungs as an index of pulmonary hyperinflation.

1. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2019;40(2):87–165. DOI: 10.1093/eurheartj/ehy394

2. Grigorieva N.Yu., Kuznetsov A.N., Sharabrin E.G. Role of chronic obstructive pulmonary disease in development of the cardiovascular continuum. Russian Heart Journal. 2012;11(2):120–2.

3. Choudhury G, Rabinovich R, MacNee W. Comorbidities and Systemic Effects of Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine. 2014;35(1):101–30. DOI: 10.1016/j.ccm.2013.10.007

4. Patel AR, Patel AR, Singh S, Singh S, Khawaja I. Global Initiative for Chronic Obstructive Lung Disease: The Changes Made. Cureus. 2019;11(6):e4985. DOI: 10.7759/cureus.4985

5. Marçôa R, Rodrigues DM, Dias M, Ladeira I, Vaz AP, Lima R et al. Classification of Chronic Obstructive Pulmonary Disease (COPD) according to the new Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017: Comparison with GOLD 2011. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2018;15(1):21–6. DOI: 10.1080/15412555.2017.1394285

6. Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, Akkerhuis KM, Kardys I, de Boer SPM et al. Relation of C-Reactive Protein to Coronary Plaque Characteristics on Grayscale, Radiofrequency Intravascular Ultrasound, and Cardiovascular Outcome in Patients With Acute Coronary Syndrome or Stable Angina Pectoris (from the ATHEROREMO-IVUS Study). The American Journal of Cardiology. 2014;114(10):1497–503. DOI: 10.1016/j.amjcard.2014.08.013

7. Mohr FW, Morice M-C, Kappetein AP, Feldman TE, Ståhle E, Colombo A et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. The Lancet. 2013;381(9867):629–38. DOI: 10.1016/S0140-6736(13)60141-5

8. Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE et al. Ankle Brachial Index Combined With Framingham Risk Score to Predict Cardiovascular Events and Mortality: A Meta-analysis. JAMA. 2008;300(2):197–208. DOI: 10.1001/jama.300.2.197

9. Bonaca MP, Bhatt DL, Storey RF, Steg PhG, Cohen M, Kuder J et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology. 2016;67(23):2719–28. DOI: 10.1016/j.jacc.2016.03.524

10. Shah MR, Hasselblad V, Gheorghiade M, Adams KF, Swedberg K, Califf RM et al. Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. The American Journal of Cardiology. 2001;88(9):987–93. DOI: 10.1016/S0002-9149(01)01975-0

11. Swiston JR, Johnson SR, Granton JT. Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: A systematic review of the literature. Respiratory Medicine. 2010;104(11):1588–607. DOI: 10.1016/j.rmed.2010.08.003

12. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. European Respiratory Journal. 2004;23(1):28–33. DOI: 10.1183/09031936.03.00034603

13. Beatty AL, Schiller NB, Whooley MA. Six-Minute Walk Test as a Prognostic Tool in Stable Coronary Heart Disease: Data From the Heart and Soul Study. Archives of Internal Medicine. 2012;172(14):1096– 102. DOI: 10.1001/archinternmed.2012.2198

14. Hassan AKM, Dimitry SR, Agban GW. Can Exercise Capacity Assessed by the 6 Minute Walk Test Predict the Development of Major Adverse Cardiac Events in Patients with STEMI after Fibrinolysis? PLoS ONE. 2014;9(6):e99035. DOI: 10.1371/journal.pone.0099035

15. Schiffrin EL, Lipman ML, Mann JFE. Chronic Kidney Disease: Effects on the Cardiovascular System. Circulation. 2007;116(1):85–97. DOI: 10.1161/CIRCULATIONAHA.106.678342

16. Savushkina O.I., Chernyak A.V. Theoretical and methodological aspects of body plethysmography and clinical applications. Bulletin physiology and pathology of respiration. 2016;60:117–24. DOI: 10.12737/20131

17. Budweiser S, Harlacher M, Pfeifer M, Jörres RA. Comorbidities and Hyperinflation Are Independent Risk Factors of Allcause Mortality in Very Severe COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2014;11(4):388–400. DOI: 10.3109/15412555.2013.836174

18. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V et al. Inspiratory-to-Total Lung Capacity Ratio Predicts Mortality in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 2005;171(6):591–7. DOI: 10.1164/rccm.200407-867OC

19. Smith BM, Prince MR, Hoffman EA, Bluemke DA, Liu C-Y, Rabinowitz D et al. Impaired Left Ventricular Filling in COPD and Emphysema: Is It the Heart or the Lungs? Chest. 2013;144(4):1143–51. DOI: 10.1378/chest.13-0183

20. Vivodtzev I, Tamisier R, Baguet J-P, Borel JC, Levy P, Pépin J-L. Arterial Stiffness in COPD. Chest. 2014;145(4):861–75. DOI: 10.1378/ chest.13-1809

21. Barr RG, Mesia-Vela S, Austin JHM, Basner RC, Keller BM, Reeves AP et al. Impaired Flow-mediated Dilation Is Associated with Low Pulmonary Function and Emphysema in Ex-smokers: The Emphysema and Cancer Action Project (EMCAP) Study. American Journal of Respiratory and Critical Care Medicine. 2007;176(12):1200–7. DOI: 10.1164/rccm.200707-980OC

22. Maclay JD, McAllister DA, Mills NL, Paterson FP, Ludlam CA, Drost EM et al. Vascular Dysfunction in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 2009;180(6):513–20. DOI: 10.1164/rccm.200903-0414OC

23. Mineo D, Ambrogi V, Cufari ME, Gambardella S, Pignotti L, Pompeo E et al. Variations of Inflammatory Mediators and α1-Antitrypsin Levels after Lung Volume Reduction Surgery for Emphysema. American Journal of Respiratory and Critical Care Medicine. 2010;181(8):806– 14. DOI: 10.1164/rccm.200910-1476OC

24. King PT. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clinical and Translational Medicine. 2015;4(1):643–50. DOI: 10.1186/s40169-015-0068-z

25. Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–63. DOI: 10.1136/thoraxjnl-2011-201518

26. Libby P, Tabas I, Fredman G, Fisher EA. Inflammation and its Resolution as Determinants of Acute Coronary Syndromes. Circulation Research. 2014;114(12):1867–79. DOI: 10.1161/CIRCRESAHA.114.302699

27. Naumov A.V., Prokofieva T.V., Saroyantc L.V., Рolunina O.S. Clinicaldiagnostic value of the study of neopterin in myocardial infarction on the background of chronic obstructive pulmonary disease. Kuban Scientific Medical Bulletin. 2018;25(2):121–6. DOI: 10.25207/1608-6228-2018-25-2-121-126

28. Wouters EFM, Groenewegen KH, Dentener MA, Vernooy JHJ. Systemic Inflammation in Chronic Obstructive Pulmonary Disease: The Role of Exacerbations. Proceedings of the American Thoracic Society. 2007;4(8):626–34. DOI: 10.1513/pats.200706-071TH

29. Zafiraki V.K., Kosmacheva E.D. Patient with coronary heart disease and chronic obstructive pulmonary disease in the era of endovascular interventions on coronary arteries. -M.-Krasnodar: Kuban State Medical University;2019. - 286 p. ISBN 978-5-903252-12-1

30. Patel ARC, Kowlessar BS, Donaldson GC, Mackay AJ, Singh R, George SN et al. Cardiovascular Risk, Myocardial Injury, and Exacerbations of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 2013;188(9):1091–9. DOI: 10.1164/rccm.201306-1170OC